Clear Rock Advisors’s RxSight RXST Stock Holding History

Clear Rock Advisors’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,275	Closed	-$213K	–	73
2023 Q4	$213K	Buy	+4,275	New	+$125K	0.1%	68

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Clear Rock Advisors's RXST Position: Q1 2024 in Review

Clear Rock Advisors sold out of RxSight (RXST) in Q1 2024, closing a stake of 4,275 shares — an estimated $213K sold.

Clear Rock Advisors first reported a position in RXST in Q4 2023 and held it in 1 quarter. The position peaked at $213K in Q4 2023. 197 funds tracked by Wall St. Rank hold RXST as of Q1 2024.

Clear Rock Advisors reported no remaining RxSight position as of Q1 2024 after selling out during the quarter.
Clear Rock Advisors sold 4,275 RxSight shares in Q1 2024, an estimated $213K.
Clear Rock Advisors first reported a position in RxSight in Q4 2023 and held it in 1 quarter.
Clear Rock Advisors's RxSight position peaked at $213K in Q4 2023.
197 funds tracked by Wall St. Rank held RxSight as of Q1 2024.

Based on Clear Rock Advisors's 13F filing for Q1 2024, filed 10 Jun 2024.